Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer

Next Previous
Trial Profile

A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AAA 817 (Primary) ; Abiraterone (Primary) ; Enzalutamide (Primary) ; Cabazitaxel; Docetaxel; Taxanes
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use; Registrational; Therapeutic Use
  • Acronyms AcTFirst
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 30 May 2025 Planned number of patients changed from 486 to 605.
  • 30 May 2025 Planned primary completion date changed from 31 Dec 2027 to 29 Feb 2028.
  • 06 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top